Market Spotlight: Obesity
発行: Datamonitor Healthcare
ページ情報: 英文 52 Pages
This Market Spotlight report covers the Obesity market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Datamonitor Healthcare estimates that in 2017, there were approximately 681.3 million prevalent cases of obesity in adults (aged 20+ years) worldwide, and expects that number to increase to 762.9 million prevalent cases by 2026.
In the same year, Datamonitor Healthcare estimates that there were 126.6 million prevalent cases of obesity in children and adolescents (aged 5-19 years) worldwide, and expects that number to increase to 134.0 million prevalent cases by 2026.
Prevalence proportions are highest in Northern America and lowest in Asia. The approved drugs in the obesity space target gastric lipase, dopamine, norepinephrine (noradrenaline), dopamine reuptake, norepinephrine (noradrenaline) reuptake/transporter, opioid receptors, GABA-A receptor, and glucagon-like peptide-1 (GLP-1) receptor. The majority of marketed drugs are administered via the oral route, with one product being available in a subcutaneous formulation.
The majority of industry-sponsored drugs in active clinical development for obesity are in Phase I, with only one drug in Phase III and one in the NDA/BLA stage.
Therapies in development for obesity focus on a wide variety of targets, with the subcutaneous route being the most common method of delivery.
High-impact upcoming events for drugs in the obesity space comprise a decentralized EU approval and an estimated EU patent expiration for Qsymia; an expected supplemental CHMP opinion and a PDUFA date for Ozempic; and topline Phase III trial results for tirzepatide.
The overall likelihood of approval of a Phase I obesity asset is 2.5%, and the average probability a drug advances from Phase III is 66.7%. Drugs, on average, take 8.5 years from Phase I to approval, compared to 9.1 years in the overall metabolic space.
The distribution of clinical trials across Phase I-IV indicates that the majority of trials for obesity have been in the early and midphases of development, with 66% of trials in Phase I-II, and 34% in Phase III-IV.
The US has a substantial lead in the number of obesity clinical trials globally. The UK leads the major European markets, while Japan has the top spot in Asia.
Clinical trial activity in the obesity space is dominated by completed trials. Novo Nordisk has the highest number of completed clinical trials for obesity, with 82 trials.
Novo Nordisk leads industry sponsors with the highest overall number of clinical trials for obesity, followed by AstraZeneca.